Articles

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›

Researchers reported results of a real-world prospective study that evaluated different geriatric assessment tools and comorbidity indices as well as standard disease-related prognostic factors in consecutive unselected patients aged >65 years with symptomatic multiple myeloma (MM). Read More ›

Researchers reported results of a population-based study examined sex, race, and age-stratified differences in incidence, mortality, and survival from 1973 to 2012 for 89,867 myeloma patients by using national epidemiologic data. Read More ›

Researchers presented results of patient-reported assessments of general health status as well as pain severity and interference using pooled data from 3 denosumab registrational trials that had enrolled patients with advanced cancers including multiple myeloma (MM). Read More ›

Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health. Read More ›

Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics. Read More ›

A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks. Read More ›

The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin. Read More ›